Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Central Nervous System Neoplasms 107Neuroblastoma 64Brain Neoplasms 64Astrocytoma 59Glioblastoma 52Oligodendroglioma 42Medulloblastoma 36Gliosarcoma 34Glioma 28Optic Nerve Glioma 20Familial ependymoma 19Choroid Plexus Neoplasms 19Sarcoma 15Rhabdoid Tumor 15Lymphoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Osteosarcoma 12Neoplasm Metastasis 12Ependymoma 12Meningioma 11Recurrence 10Melanoma 10Spinal Cord Neoplasms 9Leukemia 9Burkitt Lymphoma 9Testicular Neoplasms 8Ovarian Neoplasms 8Neoplasms 8Dendritic Cell Sarcoma, Interdigitating 8Wilms Tumor 7

Interventions

Mental Status and Dementia Tests 1Lomustine 1DNA Methylation 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Cognition Disorders × CNS × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡